Israeli innovations at Charité and BIH
In September 2019, the Israel Innovation Authority (IIA) and Charité-Universitätsmedizin Berlin and the BIH signed a Memorandum of Understanding (MoU) to cooperate in the field of technological innovation in healthcare and invite interested companies to submit applications to validate and test as well as adapt and/or optimize their healthcare related technology solutions to ultimately advance patient care. The MoU created the basis for an intensive international cooperation of Israeli innovative spirit and the scientific excellence of Charité/ BIH. After a successful first funding call of the Health Tech Pilot Program in 2020, the program is now entering its second round.
In 2020, Charité - Universitätsmedizin Berlin and the Israel Innovation Authority jointly launched a program for innovation funding and validation in the field of digital medicine/medical technology, which is now entering its second round. Under the first IIA-Health Tech Pilot Program, four contracts have already been successfully signed in October 2021. This program had a pilot character at Charité and in the future will also serve as a blueprint for collaboration with other countries to bring international innovations to the Charité.
As a result of the good and successful collaboration of the first funding call, the so-called International Health-Tech R&D and Pilot Program has been re-opened on Sept. 19, 2022. Israeli startups can apply for financial support from the Israel Innovation Authority and get access to the resources or expertise of a selected clinical project partner. The goal is to establish collaborations between excellent clinicians and scientists from Charité/BIH and Israeli startups with great innovation potential. The funded projects can include R&D activities, clinical trials in all phases, pilot studies and validation studies. The goal here is clear: beeing successful in translational science and thereby improving patient care in Germany and beyond.
Israeli companies could apply with their projects until Nov. 14, 2022. In the second phase of the program (until June 2023), Charité/BIH researchers can now plan a collaborative project with a startup to jointly apply to the IIA for funding.
We are excited about collaborating with one of the world’s leading countries in terms of innovation and start-up culture.
Dr. Sein Schmidt, Head of the BIH Clinical Research Unit at the Charité and coordinator of the Israel-project
Germany is Israel’s most important trading partner in the European Union.
H.E. Jeremy Issacharoff, Israel’s Ambassador in Germany
Project head
Dr. med. Sein Schmidt
Scientific and Medical Director, Clinical Trial Unit – Clinical Study Center (CSC), BIH, Charité
